A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : RON / recepteur d'origine nantais

[Related PubMed/MEDLINE]
Total Number of Papers: 88
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   RON  (>> Co-occurring Abbreviation)
Long Form:   recepteur d'origine nantais
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2021 Recepteur d'origine nantais contributes to the development of endometriosis via promoting epithelial-mesenchymal transition of a endometrial epithelial cells. EMT, MAPK
2020 Analysis of the Effect of Increased alpha2,3-Sialylation on RTK Activation in MKN45 Gastric Cancer Spheroids Treated with Crizotinib. RTKs
2020 Antibody-drug conjugates targeting RON receptor tyrosine kinase as a novel strategy for treatment of triple-negative breast cancer. ADCs, TNBC
2020 Lysophosphatidic Acid Upregulates Recepteur D'origine Nantais Expression and Cell Invasion via Egr-1, AP-1, and NF-kappaB Signaling in Bladder Carcinoma Cells. IBC, LPA
2020 MSP-RON Pathway: Potential Regulator of Inflammation and Innate Immunity. LPS, MSP
2020 Pathological significance of abnormal recepteur d'origine nantais and programmed death ligand 1 expression in colorectal cancer. CRC, FAHZUSM, GEO, PD-L1
2020 Prognostic role of the recepteur d'origine nantais (RON) expression in primary high-grade osteosarcoma. IHC, WB
2020 RON signalling promotes therapeutic resistance in ESR1 mutant breast cancer. AI, ET, IGF-1R, MBC, PalbR, PDX, RONi
2020 Short-form RON (sf-RON) enhances glucose metabolism to promote cell proliferation via activating β-catenin/SIX1 signaling pathway in gastric cancer. sf-RON
10  2020 Targeting RON receptor tyrosine kinase for treatment of advanced solid cancers: antibody-drug conjugates as lead drug candidates for clinical trials. ADCs, tmAbs
11  2020 The HNRNPA2B1-MST1R-Akt axis contributes to epithelial-to-mesenchymal transition in head and neck cancer. HNC, hnRNPA2B1, MST1R
12  2019 Brain Metastases from Lung Cancer: Is MET an Actionable Target? ---
13  2019 MSP-RON Signaling Is Activated in the Transition From Pancreatic Intraepithelial Neoplasia (PanIN) to Pancreatic Ductal Adenocarcinoma (PDAC). IHC, MSP, PanIN, PanINs, PDAC, PSCs
14  2019 Piperidine carbamate peptidomimetic inhibitors of the serine proteases HGFA, matriptase and hepsin. HGF, HGFA, MSP, TTSPs
15  2019 Receptor tyrosine kinase recepteur d'origine nantais as predictive marker for aggressive prostate cancer in African Americans. AAs, AR, HWs, NHWs, PCa, PSA
16  2019 Receptor tyrosine kinase, RON, promotes tumor progression by regulating EMT and the MAPK signaling pathway in human oral squamous cell carcinoma. EMT, MSP, OSCC
17  2019 RON and RONDelta160 promote gastric cancer cell proliferation, migration, and adaption to hypoxia via interaction with beta-catenin. ---
18  2019 Therapeutic anti-cancer activity of antibodies targeting sulfhydryl bond constrained epitopes on unglycosylated RON receptor tyrosine kinase. MSP, RTK
19  2018 Identification of the splice variants of Recepteur d'Origine nantais (RON) in lung cancer cell lines. EST
20  2018 Macrophage stimulating protein preserves blood brain barrier integrity after intracerebral hemorrhage through recepteur d'origine nantais dependent GAB1/Src/beta-catenin pathway activation in a mouse model. BBB, Gab1, ICH, MSP, rhMSP
21  2018 [Effects of MSP on Cell Cycle and EMT of Non-Small Cell Lung Cancer PC14]. EMT, MSP, TEM
22  2017 A missing link between RON expression and oncological outcomes in resected left-sided pancreatic cancer. VEGF
23  2017 A novel RON splice variant lacking exon 2 activates the PI3K/AKT pathway via PTEN phosphorylation in colorectal carcinoma cells. CRC, PTEN
24  2017 Effects of PTCs on nonsense-mediated mRNA decay are dependent on PTC location. MSP, NMD, PTCs
25  2017 Large Diversity of Functional Nanobodies from a Camelid Immune Library Revealed by an Alternative Analysis of Next-Generation Sequencing Data. NGS
26  2017 Qingchang Wenzhong Decoction Attenuates DSS-Induced Colitis in Rats by Reducing Inflammation and Improving Intestinal Barrier Function via Upregulating the MSP/RON Signalling Pathway. MSP, QCWZD, UC
27  2017 Role of Recepteur D'origine Nantais on Gastric Cancer Development and Progression. ---
28  2017 Splice variants of the extracellular region of RON receptor tyrosine kinase in lung cancer cell lines identified by PCR and sequencing. RTKs
29  2016 Effect of Recepteur d'Origine Nantais expression on chemosensitivity and tumor cell behavior in colorectal cancer. FU
30  2016 Elevated RON protein expression in endometriosis and disease-associated ovarian cancers. IHC
31  2016 HIV‑1 downregulates the expression and phosphorylation of receptor tyrosine kinase by targeting the NF‑kappaB pathway. HAART, HIV, MSP
32  2016 MicroRNA-375 Functions as a Tumor-Suppressor Gene in Gastric Cancer by Targeting Recepteur d'Origine Nantais. 3'-UTR, miR-375, miRNA, Rb
33  2016 Novel splicing variants of recepteur d'origine nantais (RON) tyrosine kinase involving exons 15-19 in lung cancer. RTK
34  2016 Recepteur d'Origine nantais (RON) tyrosine kinase splicing variants lacking exons 18 and 19 occur ubiquitously in lung cancer. NSCLC, SCLC
35  2016 The Complete Loss of Tyrosine Kinase Receptors MET and RON Is a Poor Prognostic Factor in Patients with Extrahepatic Cholangiocarcinoma. MET
36  2015 Chrysin inhibits cell invasion by inhibition of Recepteur d'origine Nantais via suppressing early growth response-1 and NF-kappaB transcription factor activities in gastric cancer cells. ---
37  2015 Growth-factor-driven rescue to receptor tyrosine kinase (RTK) inhibitors through Akt and Erk phosphorylation in pediatric low grade astrocytoma and ependymoma. FGFR, PDGFR, RTK, VEGFR
38  2015 Identification of short-form RON as a novel intrinsic resistance mechanism for anti-MET therapy in MET-positive gastric cancer. FGFR2, RTKs, sf-RON
39  2015 Plasma macrophage-stimulating protein and hepatocyte growth factor levels are associated with prostate cancer progression. CR, CRPC, ELISA, HGF, HGFA, MSP
40  2015 Prognostic Value of Hepatocyte Growth Factor Receptor Expression in Patients with Perihilar Cholangiocarcinoma. MET, PHC
41  2015 Recepteur d'origine nantais (RON), more than a kinase: Role in castrate-resistant prostate cancer. ADT, AR, CRPC, PCa
42  2015 Variant RONDelta160 of the RON receptor tyrosine kinase promotes the growth and invasion in vitro and in vivo in gastric cancer cell lines. MSP
43  2014 Functional consequences of the macrophage stimulating protein 689C inflammatory bowel disease risk allele. IBD, MSP
44  2014 MSP: an emerging player in metabolic syndrome. HGFL
45  2014 Regulation of Macrophage Polarization by RON Receptor Tyrosine Kinase Signaling. ---
46  2014 Structural basis for the binding specificity of human Recepteur d'Origine Nantais (RON) receptor tyrosine kinase to macrophage-stimulating protein. MSP, MSPbeta, SPI1
47  2013 EGCG inhibits recepteur d'origine nantais expression by suppressing Egr-1 in gastric cancer cells. ECG, EGC, EGCG, PMA
48  2013 Host genetic background impacts modulation of the TLR4 pathway by RON in tissue-associated macrophages. MSP, TLRs
49  2013 Integrative genomic analyses of recepteur d'origine nantais and its prognostic value in cancer. IPT, PSI, RTK, Sema, SNPs
50  2013 RON (recepteur d'origine nantais) expression and its association with tumor progression in laryngeal squamous cell carcinoma. MSP, SCC
51  2013 RON confers lapatinib resistance in HER2-positive breast cancer cells. siRNA
52  2013 RON receptor tyrosine kinase, a negative regulator of inflammation, is decreased during simian immunodeficiency virus-associated central nervous system disease. ---
53  2012 CD10+ and CK7/RON- immunophenotype distinguishes renal cell carcinoma, conventional type with eosinophilic morphology from its mimickers. AUC, chRCC, CK7, Ksp-cadherin, OR, RO
54  2012 Expression and mutational status of RON in neoplastic lesions of the breast: analysis of MSP/RON signaling in ductal carcinoma in situ and invasive ductal carcinoma. MSP, PCR-SSCP
55  2012 Expression of RON in colorectal cancer and its relationships with tumor cell behavior and prognosis. siRNA
56  2012 Expression of the recepteur d'originenantais receptor tyrosine kinase in non-small cell lung cancer and its clinical significance. IHC, NSCLC, RT-PCR, RTK
57  2012 Expression of the receptor tyrosine kinase recepteur d'origine nantais and its association with tumor progression in hypopharyngeal cancer. PARP, SCC
58  2012 RON is associated with tumor progression via the inhibition of apoptosis and cell cycle arrest in human gastric cancer. MAPK
59  2012 Sensitivity of selected human tumor models to PF-04217903, a novel selective c-Met kinase inhibitor. HGF, shRNA
60  2012 The RON-receptor regulates pancreatic cancer cell migration through phosphorylation-dependent breakdown of the hemidesmosome. ECM, ITGB4, MEK, PI3, shRNA
61  2012 The short form of RON is expressed in acute myeloid leukemia and sensitizes leukemic cells to cMET inhibitors. AML, AZA, sf, TKs
62  2011 Knockdown of RON inhibits AP-1 activity and induces apoptosis and cell cycle arrest through the modulation of Akt/FoxO signaling in human colorectal cancer cells. AP-1, FOXO, siRNA
63  2011 Novel function of transcription factor Nrf2 as an inhibitor of RON tyrosine kinase receptor-mediated cancer cell invasion. ChIP, SFN
64  2011 Receptor tyrosine kinase pathway analysis sheds light on similarities between clear-cell sarcoma and metastatic melanoma. CCS, MM, RTK, sf
65  2011 Requirement for LMP1-induced RON receptor tyrosine kinase in Epstein-Barr virus-mediated B-cell proliferation. CTAR1, LCLs, LMP1, PTLD
66  2011 Small interfering RNA-directed targeting of RON alters invasive and oncogenic phenotypes of human hepatocellular carcinoma cells. ERK, HCC, siRNA
67  2011 Splicing factor hnRNPH drives an oncogenic splicing switch in gliomas. GBM, IG20
68  2011 Upregulation of recepteur d'origine nantais tyrosine kinase and cell invasiveness via early growth response-1 in gastric cancer cells. PMA
69  2010 MSP-induced RON activation upregulates uPAR expression and cell invasiveness via MAPK, AP-1 and NF-kappaB signals in gastric cancer cells. AP, JNK, MAPK, NF-kappaB, siRNA, uPAR
70  2010 Small interfering RNA targeting of Recepteur d'Origine Nantais induces apoptosis via modulation of nuclear factor-kappaB and Bcl-2 family in gastric cancer cells. NF-kappaB, siRNA
71  2010 Therapeutic effects of the Sp1 inhibitor mithramycin A in glioblastoma. MIC, MitA, MMP, mRNA, TRAIL, VEGF, XIAP
72  2009 RON receptor tyrosine kinase in human gliomas: expression, function, and identification of a novel soluble splice variant. GBM, MSP
73  2008 Activation of RON differentially regulates claudin expression and localization: role of claudin-1 in RON-mediated epithelial cell motility. MDCK
74  2008 Curcumin blocks RON tyrosine kinase-mediated invasion of breast carcinoma cells. MSP
75  2008 Expression of the RON receptor tyrosine kinase and its association with gastric carcinoma versus normal gastric tissues. IHC, MSP
76  2008 HIV-1 Tat mediates degradation of RON receptor tyrosine kinase, a regulator of inflammation. ---
77  2008 Identification of a novel recepteur d'origine nantais/c-met small-molecule kinase inhibitor with antitumor activity in vivo. ---
78  2008 Prognostic role of the recepteur d'origine nantais (RON) expression in ovarian cancer patients. ---
79  2008 The prognostic significance of RON and MET receptor coexpression in patients with colorectal cancer. ---
80  2008 The RON receptor tyrosine kinase promotes MSP-independent cell spreading and survival in breast epithelial cells. RTK
81  2007 Apical oxidative hyaluronan degradation stimulates airway ciliary beating via RHAMM and RON. ALI, CBF, HA, MSP, RHAMM, SOD, X/XO
82  2007 Neutralization of macrophage-stimulating protein ameliorates renal injury in anti-thy 1 glomerulonephritis. MSP
83  2007 The RON receptor tyrosine kinase mediates oncogenic phenotypes in pancreatic cancer cells and is increasingly expressed during pancreatic cancer progression. HGFL, PanIN
84  2006 Oncogenesis of RON receptor tyrosine kinase: a molecular target for malignant epithelial cancers. MSP, RTK
85  2005 Co-expression of RON and MET is a prognostic indicator for patients with transitional-cell carcinoma of the bladder. MET
86  2004 Collaborative activities of macrophage-stimulating protein and transforming growth factor-beta1 in induction of epithelial to mesenchymal transition: roles of the RON receptor tyrosine kinase. alpha-SMA, EMT, TGF
87  2004 Macrophage-stimulating protein, the ligand for the stem cell-derived tyrosine kinase/RON receptor tyrosine kinase, inhibits IL-12 production by primary peritoneal macrophages stimulated with IFN-gamma and lipopolysaccharide. MSP
88  1999 Characterization of two monoclonal antibodies against the RON tyrosine kinase receptor. HGF, mAbs, MDCK, MFI, MSP